Page 166 - 南京医科大学学报自然科学版
P. 166
第
第40卷第6期41卷第3期
2021
·472 · 南 京 医 科 大 学 学 报 2020年6月年3月
质量评分。发达国家血友病的治疗基本采用长期 2014,20(6):794-799
标准剂量或大剂量预防治疗方案,长期预防治疗是 [8] BRAY G L,GOMPERTS E D,COURTER S,et al. A mul⁃
改善血友病患者生活质量的一个关键因素。而沉 ticenter study of recombinant factor Ⅷ(recombinate):
重的经济负担一直是众多血友病家庭需要面对的 safety,efficacy,and inhibitor risk in previously untreated
patients with hemophilia A. The Recombinate Study
问题。本组患儿前 4 年得益于居民医保的高额覆
Group[J]. Blood,1994,83(9):2428-2435
盖,大大减少了预防治疗对血友病家庭的经济负
[9] OLDENBURG J,ZIMMERMANN R,KATSAROU O,et
担。但 2019 年起新医保政策大幅下调血友病患者
al. Controlled,cross⁃sectional MRI evaluation of joint sta⁃
的报销额度,随访患者家庭均表示预防治疗成为血 tus in severe haemophilia A patients treated with prophy⁃
友病家庭沉重的经济负担。SEC量表的结果主要反 laxis vs. on demand[J]. Haemophilia,2015,21(2):171-
映患者的社会和经济背景相关信息,提示经济负担 179
会影响患者的HRQoL。另一项队列研究表明血友病 [10] TANG L,WU R,SUN J,et al. Short⁃term low⁃dose secon⁃
患者的 HRQoL受血友病严重程度、ABR、身体活动限 dary prophylaxis for severe/moderate haemophilia A chil⁃
制、经济负担和治疗的影响,而预防治疗是改善患者 dren is beneficial to reduce bleed and improve daily activ⁃
ity,but there are obstacle in its execution:a multi⁃centre
预后的关键因素 。预防治疗虽不能逆转已经存在
[20]
pilot study in China[J]. Haemophilia,2013,19(1):27-
的关节异常,但可以控制并减少出血频率,尽可能
34
地改善患者生活质量。
[11]KAVAKLI K,YANG R,RUSEN L,et al. Prophylaxis vs.
本文对 10 例中间型、重型血友病 A 随访 5 年的 on⁃demand treatment with BAY 81⁃8973,a full⁃length
前瞻性观察分析表明,rFⅧ标准剂量预防治疗中间 plasma protein⁃free recombinant factor Ⅷ product:results
型、重型血友病A,患儿ABR和AJBR较按需治疗期 from a randomized trial(LEOPOLD II)[J]. J Thromb Hae⁃
有下降趋势,药物安全性好,抑制物产生率低,预防 most,2015,13(3):360-369
治疗期间患儿生活质量较按需治疗期有所提高。 [12] WANG X F,ZHAO Y Q,YANG R C,et al. The preva⁃
lence of factor Ⅷ inhibitors and genetic aspects of inhibi⁃
[参考文献]
tor development in Chinese patients with haemophilia A
[1] MANNUCCI P M,TUDDENHAM E G. The hemophilias⁃⁃ [J]. Haemophilia,2010,16(4):632-639
from royal genes to gene therapy[J]. N Engl J Med,2001, [13] EWENSTEIN B M,GOMPERTS E D,PEARSON S,et al.
344(23):1773-1779 Inhibitor development in patients receiving recombinant
[2] SRIVASTAVA A,BREWER A K,MAUSER ⁃ BUN⁃ factor Ⅷ(recombinate rAHF/Bioclate):a prospective
SCHOTEN E P,et al. Guidelines for the management of pharmacovigilance study[J]. Haemophilia,2004,10(5):
hemophilia[J]. Haemophilia,2013,19(1):E1-E47 491-498
[3] MAKRIS M,KASPER C. The world federation of hemo⁃ [14] GOMEZ K,KLAMROTH R,MAHLANGU J,et al. Key
philia guideline on management of haemophilia[J]. Hae⁃ issues in inhibitor management in patients with haemo⁃
mophilia,2013,19(1):1 philia[J]. Blood Transfus,2014,12(Suppl 1):s319-s329
[4] FUKUTAKE K,TAKI M,MATSUSHITA T,et al. Inhibi⁃ [15] KEMPTON C L. Inhibitors in previously treated patients:
tor development,safety and efficacy of Advate(®) a review of the literature[J]. Haemophilia,2010,16(12):
among previously treated patients with hemophilia A in a 61-65
postmarketing surveillance in Japan[J]. Int J Hematol, [16]LEISSINGER C A. Advances in the clinical management
2019,109(3):336-345 of inhibitors in hemophilia A and B[J]. Semin Hematol,
[5] 王诗轩,孙 竞,李长钢,等. 重组人凝血因子Ⅷ治疗 2016,53(1):20-27
411 例中重型血友病 A 患者的抑制物产生及安全性的 [17] ZHANG H,HUANG J,KONG X,et al. Health ⁃ related
回顾性分析[J]. 临床血液学杂志,2018,31(1):29-33 quality of life in children with haemophilia in China:a 4⁃
[6] YOUNG N L,WAKEFIELD C,BURKE T A,et al. Updat⁃ year follow⁃up prospective cohort study[J]. Health Qual
ing the Canadian hemophilia outcomes ⁃ kids life assess⁃ Life Outcomes,2019,17(1):28
ment tool(CHO ⁃ KLAT Version2.0)[J]. Value Health, [18] MCCUSKER P J,FISCHER K,HOLZHAUER S,et al. In⁃
2013,16(5):837-841 ternational cross⁃cultural validation study of the Canadian
[7] WU R,ZHANG J,SUN J,et al. Validation of the Chinese haemophilia outcomes:kids’life assessment tool[J].
version of the Canadian haemophilia outcomes⁃kids’life Haemophilia,2015,21(3):351-357
assessment tool(the CHO ⁃ KLAT)[J]. Haemophilia, [收稿日期] 2020-05-25